Virpax Pharmaceuticals Inc. (Nasdaq:VRPX) Email Format

Pharmaceutical ManufacturingPennsylvania, United States11-50 Employees

Virpax Pharmaceuticals Inc. is a pharmaceutical company focused on developing non-addictive pain management therapies and other targeted medical treatments. Its lead candidate, Probudur, aims to provide sustained local anesthesia at wound or incision sites for up to 96 hours, using a proprietary liposomal delivery platform to address post-operative pain. The company is engaged in collaborations with government and research organizations to advance differentiated options for pain management, epilepsy, and other conditions, including efforts related to non-addictive medications for various pain states and pediatric epilepsy. Based in Berwyn, Pennsylvania, the firm positions itself within the pharmaceutical manufacturing sector, pursuing development across multiple therapeutic areas that target unmet global needs, including rare diseases. In addition to its core pain-management programs, Virpax has pursued initiatives in areas such as epilepsy and focused on exploring delivery approaches for other indications through partnerships and program development. The company’s activities are conducted in the context of a small to mid-sized biotechnology enterprise with ongoing programs and collaborations intended to advance its drug-delivery platforms and therapeutic candidates.

Get verified Virpax Pharmaceuticals Inc. (Nasdaq:VRPX) emails free

Company overview Employee directory